治疗慢性淋巴细胞白血病新药venetoclaxVenetoclax,A New Drug in the Treatments of Chronic Lymphocytic Leukemia
张志叶,夏阳
ZHANG Zhiye,XIA Yang
摘要(Abstract)：
venetoclax是首个B细胞淋巴瘤-2基因抑制剂(Bcl-2),用于有17p基因缺失的慢性淋巴细胞白血病(CLL)且曾经接受过至少1种药物治疗的患者。于2016年4月11日被美国食品药品监督管理局(FDA)批准上市。笔者对其作用机制、药效学、药动学、临床研究、安全性等方面进行综述。
Venetoclax is a B-cell lymphoma-2 inhibitors for the treatment of patients with chronic lymphocytic leukemia( CLL) with17 p deletion,who have received at least one prior therapy. This indication is approved by the U. S. FDA on April 11,2016. In this review,the mechanism of action,pharmacodynamics,pharmacokinetics,clinical studies and safety of venetoclax were summarized.
关键词(KeyWords)：
venetoclax;慢性淋巴性白血病;B细胞淋巴瘤-2基因抑制剂(Bcl-2抑制剂);临床研究
venetoclax;chronic lymphocytic leukemia(CLL);B-cell lymphoma-2 inhibitor(Bcl-2);clinical studies
基金项目(Foundation):
作者(Author):
张志叶,夏阳
ZHANG Zhiye,XIA Yang
参考文献(References)：
- [1]刘声财,汪英颖,刘尚勤,等.慢性淋巴细胞白血病诊治指南(解读)[J].2015,32(12):862-864.
- [2]US Food and Drug Administration.VENCLEXTA(venetoclax)tablets[EB/OL].[2016-04-11].http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s000lbl.pdf.
- [3]药讯快递,Venetoclax全球第一个Bcl-2抑制剂[J].临床合理用药,2016,9(5):136-136.
- [4]李杨玲,张博,林能明,等.靶向Bcl-2小分子抑制剂在肿瘤治疗中的研究进展[J].中国药房,2016,27(17):2436-2439.
- [5]Michelle M.Williams,Rebecca S.Cook.Bcl-2 family proteins in breast development and cancer:could Mcl-1 targeting overcome therapeutic resistance[J].Oncotarget,2015,6(6):3519-3530.
- [6]Phoebe Starr.Venetoclax Shows Strong Activity in CLL[J].Am Health Drug Benefits,2016,9(Spec Issue):21-21.
- [7]Walter Alexander.American Society of Hematology 2015 Annual Meeting[J].P T.2016,41(2):120-125.
- [8]Freise K J,Dunbar M,Jones A K,et al.Venetoclax does not prolong the QT interval in patients with hematological malignancies:an exposure-response analysis[J].Cancer Chemother Pharmacol,2016,78(4):847-53.
- [9]Weiss J,Gajek T,K9hler BC,et al.Venetoclax(ABT-199)Might Act as a Perpetrator in Pharmacokinetic Drug–Drug Interactions[J].Pharmaceutics,2016,8(1):5-18.
- [10]Salem A H,Hu B,Freise K J,et al.Evaluation of the Pharmacokinetic Interaction between Venetoclax,a Selective BCL-2 Inhibitor,and Warfarin in Healthy Volunteers[J].Clin Drug Investig,2016Dec 2.DOI:10.1007/s40261-016-0485-9.
- [11]Anderson M A,Deng J,Seymour J F,et al.The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism[J].Blood,2016 Jun23,127(25):3215-3224.
- [12]Roberts A W,Davids M S,Pagel J M,et al.Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia[J].N Engl J Med,2016,374(4):311-322.
- [13]Cang S,Iragavarapu C,Savooji J,et al.ABT-199(venetoclax)and BCL-2 inhibitors in clinical development[J].J Hematol Oncol,2015,8(1):129-137.
- [14]New drugs,Drug and Device News[J].P T,2016,41(5):277-278.
- [15]Freise K J,Jones A K,Menon R M et al.Relationship between venetoclax exposure,rituximab coadministration,and progressionfree survival in patients with relapsed or refractory chronic lymphocytic leukemia:demonstration of synergy[J].Hematol Oncol,2016Dec 16.DOI:10.1002/hon.2373.
- [16]夏训明.美国FDA批准Venclexta(venetoclax)治疗慢性淋巴细胞白血病[J].广东药学院学报,2016,32(2):209-209.